Drug-Resistant candida glabrata infection in cancer patients

Emerging Infectious Diseases

Volumn 20, Issue 11, 2014, Pages 1833-1840

  Farmakiotis, Dimitrios ^a   Tarrand, Jeffrey J ^a   Kontoyiannis, Dimitrios P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANCER PATIENT; CANDIDA GLABRATA; CANDIDIASIS; CLINICAL FEATURE; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; LEUKEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTOPENIA; MORTALITY; NEUTROPENIA; PARENTERAL NUTRITION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; ANTIFUNGAL RESISTANCE; CAUSE OF DEATH; CHILD; COMPLICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; NEOPLASM; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CAUSE OF DEATH; CHILD; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 84908086435     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2011.140685     Document Type: Article

References (31)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. http://dx.doi.org/10.1086/596757
2. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine. 2003;82:309–21. http://dx.doi.org/10.1097/01.md.0000091182.93122.8e
3. Hachem R, Hannah H, Kontoyiannis D, Jang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–9. http://dx.doi.org/10.1002/cncr.23466
4. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad I., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52. http://dx.doi.org/10.1002/cncr.24507
5. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH. Candidemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65:1042–51. http://dx.doi.org/10.1093/jac/dkq053
6. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated MIC. Clin Infect Dis. 2013;56:1724–32. http://dx.doi.org/10.1093/cid/cit136
7. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014;33:673–88. http://dx.doi.org/10.1007/s10096-013-2009-3
8. Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen YL, et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 2012;8:e1002718. http://dx.doi.org/10.1371/journal.ppat.1002718
9. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multi-drug resistant Candida. Clin Infect Dis. 2013;56:1733–4. http://dx.doi.org/10.1093/cid/cit140
10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed. M27–S4. Wayne (PA): The Institute; 2012.
11. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3–13. http://dx.doi.org/10.1016/j.amjmed.2011.11.001
12. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. The impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014;52:994–7. http://dx.doi.org/10.1128/JCM.03044-13
13. Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78–81. http://dx.doi.org/10.1016/j.ijantimicag.2013.09.005
14. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother. 2013;57:3528–35. http://dx.doi.org/10.1128/AAC.00136-13
15. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance. Antimicrob Agents Chemother. 2013;57:6361–5. http://dx.doi.org/10.1128/AAC.01451-13
16. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. M27–A3. Wayne (PA): The Institute; 2008.
17. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata; risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59:819–25.
18. Stratman RC, Martin CA, Rapp RP, Berger R, Magnuson B. Candidemia incidence in recipients of parenteral nutrition. Nutr Clin Pract. 2010;25:282–9. http://dx.doi.org/10. 1177/0884533610368704
19. Luzzati R, Cavinato S, Giangreco M, Granà G, Centonze S, Deiana ML, et al. Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case–control study. Mycoses. 2013;56:664–71. http://dx.doi.org/10.1111/myc.12090
20. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50:1199–203. http://dx.doi.org/10.1128/JCM.06112-11
21. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, et al. The role of FKS mutations in C. glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58:4690–6.
22. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Application of the combined CLSI/EUCAST breakpoints for azole and echinocandin susceptibilities of Candida isolates in a tertiary cancer center: the emerging threat of multidrug resistance. In: Book of Abstracts of the 12th ASM Conference on Candida and Candidiasis;New Orleans, LA; 2014 Mar 26–30. Oral presentation S8:5, p. 60 [cited 2014 Jun 19].http://conferences.asm.org/images/2014_candida_web_program.pdf
23. Miyazaki T. A single amino acid mutation in IPI1 confers multi-antifungal resistance without affecting virulence in Candida glabrata. In: Book of Abstracts of the 12th ASM Conference on Candida and Candidiasis; New Orleans, LA; 2014 Mar 26–30. Invited oral presentation S10C, p. 73 [cited 2014 Jun 19]. http://cofnerences.asm. org/images/2014_candida_web_program.pdf
24. Schulz B, Knobloch M, Weber K, Ruhnke M. Doxorubicin selects for fluconazole-resistant petite mutants in Candida glabrata isolates. Int J Med Microbiol. 2012;302:155–61. http://dx.doi.org/10.1016/j.ijmm.2012.04.002
25. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518–23. http://dx.doi.org/10.1128/AAC.05947-11
26. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011;204:626–35. http://dx.doi.org/10.1093/infdis/jir351
27. Fernández-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, et al. In-vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. Antimicrob Agents Chemotherapy. 2014;58:3646–9.
28. Ferrari S, Sanguinetti M, De Bernardis F, Torelli R, Posteraro B, Vandeputte P, et al. Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother. 2011;55:1852–60. http://dx.doi.org/10.1128/AAC.01271-10
29. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, et al. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother. 2014;58:1897–906. http://dx.doi. org/10.1128/AAC.02163-13
30. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–42. http://dx.doi.org/10.1128/AAC.01519-13
31. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862–9. http://dx.doi.org/10.1128/AAC.00027-12